Table 2.

A. Normal vs cancer ducts–QM-MSP/90th percentile rank method
Gene panelSensitivity (%, ratio; 95% CI)Specificity (%, ratio; 95% CI)Classification accuracy (%, ratio; 95% CI)Papillomas (% neg; 95% CI)Threshold*
3-gene86 (6/7; 42-100)93 (26/28; 77-99)91 (32/35; 77-98)78 (21/27; 58-91)2.7
6-gene86 (6/7; 42-100)93 (26/28; 77-99)91 (32/35; 77-98)67 (18/27; 46-83)6.2
11-gene86 (6/7; 42-100)93 (26/28; 77-99)91 (32/35; 77-98)67 (18/27; 46-83)7.8
B. Benign vs Cancer ducts -QM-MSP/ROC analysis method
Gene panelSensitivity (%, ratio; 95% CI)Specificity (%, ratio; 95% CI)Classification accuracy (%, ratio; 95% CI)AUC (95% CI)Threshold
3-gene100 (7/7; 59-100)72 (21/29; 53-87)78 (28/36; 61-90)0.91 (0.80-1.00)2.6
6-gene100 (7/7; 59-100)66 (19/29; 46-82)72 (26/36; 55-86)0.88 (0.76-1.00)5.5
11-gene100 (7/7; 59-100)55 (16/29; 36-74)64 (23/36; 46-79)0.84 (0.69-0.99)5.0
  • NOTE: 3-gene: RASSF1A, TWIST1, and HIN1; 6-gene: RASSFIA, TWIST1, HIN1, APC1, CYCLIN D2, and RARβ; 11-gene panel: RASSFIA, TWIST1, HIN1, APC1, CYCLIN D2, RARβ, CDH1, BRCA1, BRCA2, and ERα; sensitivity, number of true positives divided by the number of true positives plus false negatives; specificity, number of true negatives divided by the number of true negatives plus false positives; classification accuracy, number of ducts correctly identified/total number of ducts; AUC, the predictive power of the test.

  • * The upper threshold of reference range of methylation in ductoscopy cells was defined by the 90th percentile rank of methylation in ducts with.

  • The upper threshold of benign % methylation in ductoscopy cells was defined by ROC analysis of methylation in ducts.